Pain

After FDA committees vote 27-0 against recommending the NDA for NKTR-181, Nektar Therapeutics announced they were withdrawing the application and canceling the program.

Northwell Health will focus on 2 different clinical strategies for monitoring and treating severe traumatic brain injuries.

A look back at the developments and interviews that caught the most attention this year.

The oral CGRP antagonist becomes the first in its class approved for the indication.

In a new study, investigators examine whether a low FODMAP diet could be beneficial for patients suffering from quiescent IBD.

The approval allows Medtronic to move forward with the IN.PACT AV balloon to treat failing arteriovenous access for patients with end-stage renal disease undergoing dialysis.

The new approval grants BD the ability to move forward with a new device aimed at repairing abdominal hernias.

During AHA, investigators suggest ways to improve care for women in regard to diabetic and cardiovascular interventions.

Studies are ongoing to test the safety and efficacy of treating primary hyperoxaluria type 1 patients with lumasiran.

Abdul Abdellatif, MD, discusses during Kidney Week some treatment options for patients with gout.

Todd Alexander, MD, discusses a relatively new field of nephrology research during Kidney Week.

Daniel Clauw, MD, of the University of Michigan, discusses the impact public perception has had on pain management practices for patients with rheumatic diseases and chronic pain.

A 19-year analysis presented at ACR 2019 has found opioid use disorder hospitalizations among some rheumatic diseases have increased more than 30-fold since 1998.

A new study has found use of methotrexate could reduce joint damage progression and facilitate bone remodeling in patients with hand osteoarthritis.

A new study presented at ACR 2019 has found spending on bDMARDs nearly doubled between 2012 and 2016, with post-market drug price changes driving most of the increase.

Brad Rovin, MD, of The Ohio State University, discusses during Kidney Week what is needed for better outcomes for patients with lupus nephritis.

A new study from Northwestern is highlighting the disparities in postpartum pain management received by non-Hispanic black and Hispanic women compared to their white counterparts.

A new study has found use of ketamine for treatment of acute or chronic pain does not increase risk for hepatotoxicity or other adverse drug events, as some previous research has suggested.

The FDA is allowing Rocket Pharmaceuticals to conduct a global phase I study testing a new treatment approach for Pyruvate Kinase Deficiency.

Romosozumab joins the growing list of monoclonal antibody drugs that treat osteoporosis in postmenopausal women.

Data from a 961-patient study shows that ustekinumab can induce and maintain remission for patients with moderate-to-severe ulcerative colitis.

With ARBs linked to a higher risk of suicide, investigators suggest treating diseases like hypertension, chronic kidney disease, heart failure, and diabetes with ACEIs instead.

In a phase 3b study, 75% of patients using HTX-011 were discharged without opioids following a total knee arthroplasty.

In a dose finding trial, 100 μg of sprifermin every 6 or 12 months is proven to boost femorotibial joint cartilage thickness in patients suffering from osteoarthritis.

The monoclonal antibody class of drugs could help osteoporosis patients prevent fractures.

Recent measures in the UK has led to a drop in IBD patients using corticosteroids to excess.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

In a new randomized study, investigators compare 2 hip surgeries for elderly patients with a displaced femoral neck fracture.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.